Search results
Results from the WOW.Com Content Network
Since 2010, there is also a Bethesda system used for cytopathology of thyroid nodules, which is called The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC or BSRTC). Like TBS, it was the result of a conference sponsored by the NIH and is published in book editions (currently by Springer).
Cytopathology suspicious for Hürthle cell neoplasm (Bethesda category IV, rather than Hürthle cell hyperplasia), Pap stain. [5]Hürthle cell neoplasms can be separated into Hürthle cell adenomas and carcinomas, which are respectively benign and malignant tumors arising from the follicular epithelium of the thyroid gland. [6]
[2] [3] A total thyroidectomy is often performed, this results in a complete removal of the thyroid. Some patients may only have half of their thyroid removed, this is known as a thyroid lobectomy. Another treatment option includes pharmacological suppression of thyroid hormone. The thyroid gland is responsible for producing the thyroid ...
Pages for logged out editors learn more. Contributions; Talk; Bethesda system for reporting thyroid cytopathology
Colloid nodules may be initially identified as an unspecified kind of thyroid nodule. Follow-up examinations typically include an ultrasound if it is unclear whether or not there really is a nodule present. Once the presence of a nodule has been confirmed, the determination of the kind of thyroid nodule is done by fine needle aspiration biopsy. [7]
Histopathology of NIFTP, H&E stain. [1]Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is an indolent thyroid tumor that was previously classified as an encapsulated follicular variant of papillary thyroid carcinoma, [2] necessitating a new classification as it was recognized that encapsulated tumors without invasion have an indolent behavior, [2] and may ...
Papillary thyroid cancer (magnified at right) arising within ectopic thyroid tissue of a thyroglossal cyst is a rare occurrence (less than 1% of such cysts). [ 38 ] According to Surveillance, Epidemiology, and End Results (SEER), the incidence of papillary cancer has increased from 4.8 to 14.9 per 100,000 from 1975 to 2012.
Dr. Yuri Nikiforov (Russian: Юрий Ефимович Никифоров, romanized: Yury Yefimovich Nikiforov; born 12 September 1962) is an American scientist who revolutionized the understanding of thyroid cancer, most recently winning a two-year battle in which the World Health Organization agreed in 2017 to reclassify non-invasive thyroid tumors to non-cancerogenic liaisons.